Literature DB >> 1914381

Disposition of drugs in cystic fibrosis. II. Hepatic blood flow.

T A O'Sullivan1, L A Bauer, J R Horn, B K Zierler, D E Strandness, J Williams-Warren, A L Smith, J D Unadkat.   

Abstract

To determine whether the increased clearance of high extraction-ratio drugs in cystic fibrosis is caused by an increase in hepatic blood flow, the blood flow in main branches of the hepatic vein and portal vein was measured by use of noninvasive duplex ultrasound scanning in 10 adult subjects with cystic fibrosis and in 10 healthy age-, gender-, and height-matched control subjects. No statistically significant differences between subjects with cystic fibrosis and control subjects were detected in either the hepatic vein (217 +/- 103 ml/min for subjects with cystic fibrosis versus 211 +/- 135 ml/min for control subjects) or the portal vein (205 +/- 114 ml/min for subjects with cystic fibrosis versus 190 +/- 101 ml/min for control subjects) blood flows. These data indicate that a large (greater than or equal to 100%) increase in the clearance of high extraction-ratio drugs in patients with cystic fibrosis is unlikely to be primarily caused by an increase in hepatic blood flow. It is probable that alternative mechanisms such as enhanced secretory or metabolic pathways account in large part for increases in clearance of high extraction-ratio drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914381     DOI: 10.1038/clpt.1991.163

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

2.  Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice.

Authors:  S G Kulkarni; A A Pegram; P C Smith
Journal:  AAPS PharmSci       Date:  2000

Review 3.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

4.  Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.

Authors:  A E Cribb; B Tsui; R Isbrucker; R T Michael; C T Gillespie; J Brown-Bonomo; P Barrett; T Levatte; K W Renton
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

5.  Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

Authors:  L A Bauer; T O'Sullivan; W G Reiss; J R Horn; K Opheim; D E Strandness; R L Carithers
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

6.  Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.

Authors:  Brian Cicali; Tao Long; Sarah Kim; Rodrigo Cristofoletti
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.